Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and clinicopathological correlates from EFTISARC-NEO, the investigator-initiated Phase II trial of eftilagimod alfa (efti) plus KEYTRUDA® (pembrolizumab) and radiotherapy as neoadjuvant treatment for resectable soft tissue sarcoma (STS). Further detail and analyses will be presented in a poster discussion session on 19 November 2026 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, being held from 18–21 November 2026 in Seoul, South Korea.
Covered in this story
Analyst targets on Custom Truck One Source Inc
- DA Davidson: at $10.5 · target $13 by Oct 2027 · Buy via Investing.com
- Cantor Fitzgerald: at $10.5 · target $14 by Oct 2027 · Overweight via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CTOS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Custom Truck One Source Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.